Ações Illumina, Inc. (ILMN) — é um bom negócio?

Ações Illumina, Inc. (ILMN) — é um bom negócio? — InspectStocks

Just reported

Q3 FY2027 results

From Illumina's results release of 29 de outubro de 2026; its quarterly report has since been filed.

Revenue
Actual
US$ 1,13B
+4,2% y/y
-2,6% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$ 1,43
+46% y/y
+5,9% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$ 305M
+34% y/y
+24% q/q
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Como ganha dinheiro

Sequencing consumables73%
Services and other16%
Sequencing instruments11%

As participações na receita são estimativas para quarter ended 2026-03-31, não números de um relatório oficial.

Concorre com

300676BGI Genomics

O que vende6

NovaSeq X
A high-throughput DNA-sequencing machine used by customers that need to process large numbers of samples.
MiSeq i100
A lower-throughput DNA-sequencing machine for labs running smaller or more project-based batches.
NovaSeq 6000
A high-throughput DNA-sequencing machine that some customers continue to use alongside newer systems.

Mostrar mais 3

StrataMap Spatial
A sequencing-based workflow that helps researchers study biological activity in specific locations within tissue.
SomaScan and SomaSeq
Tools for measuring proteins and connecting protein measurements with genetic information.
Billion Cell Atlas
A large collection of data on how cells respond to genetic changes, sold to drug companies for biological research and drug discovery.

Quem compra3

Clinical laboratories and hospitals buy sequencing machines and supplies for testing, including cancer, inherited-disease and screening applications.
Universities and research laboratories buy sequencing equipment and supplies to study genes, cells and biological processes.
Drug companies buy sequencing-related services and biological data to support research and drug discovery.

Em que se apoia e o que pode quebrá-lo

Do que o negócio depende

1Repeat consumables purchases depend on customers using Illumina machines and running samples on them.
2Clinical sequencing demand and purchases by large clinical customers are important sources of business growth.
3Instrument production depends on access to memory and other critical components, while freight costs affect expenses.
4Business in China is affected by restrictions associated with China's unreliable entity list.

O que pode dar errado

1If clinical laboratories expand sequencing use more slowly or run fewer samples, demand for sequencing supplies could fall.
2Uncertain research funding can reduce purchases by universities and research customers; research and applied consumables were declining in the quarter discussed on the call.
3Higher memory and freight costs, or difficulty obtaining critical components, can increase costs and disrupt instrument supply.

Demonstrações financeiras completas →

Sobre a Illumina, Inc.

Illumina makes machines that read DNA and sells the chemicals and other supplies customers use to run samples on them. Hospitals and clinical laboratories use sequencing for applications such as cancer testing, inherited-disease testing and screening; researchers and drug companies use it to study biology and develop medicines. Illumina also sells tools for measuring proteins and provides biological data and related services.

Sede: San Diego, California
Fundada em: 1998
Listada em: Nasdaq
Fim do exercício: Sunday nearest December 31

Construído a partir dos próprios documentos de Illumina, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.

Just reported

Q3 FY2027 results

From Illumina's results release of 29 de outubro de 2026; its quarterly report has since been filed.

Revenue
Actual
US$ 1,13B
+4,2% y/y
-2,6% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$ 1,43
+46% y/y
+5,9% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$ 305M
+34% y/y
+24% q/q
Guided
—
No guide given

Keep exploring

The themes Illumina is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Diagnostics and Research

Graded A or B and worth $2B or more: A first, then the largest.

All 42 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises